Borja Jiménez-Lasheras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Borja Jiménez-Lasheras has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Asis Palazon
Cancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, Spain
68 shared publications - Leire Egia-Mendikute
Cancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, Spain
68 shared publications - Paloma Velasco-Beltrán
Cancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, Derio, Spain
67 shared publications - Alessia Pellerino
Division of Neuro-Oncology, Department of Neuroscience “Rita Levi Montalcini”, University and City of Health and Science Hospital, Torino, Italy
36 shared publications - Alfonso Calvo
Program in Solid Tumors, Center for Applied Medical Research (CIMA), Cancer Center Clinica Universidad de Navarra (CCUN), University of Navarra, Avenida de Pío XII, 55, 31008 Pamplona, Spain
36 shared publications - Ana de Pablos-Aragoneses
Spanish National Cancer Research Centre New York, NY United States
36 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Immunoblot analysis of β-catenin in TWS119-treated or DMSO control T cells, NFAT activity assessed by eGFP fluorescence in non-activated or activated TPR cells treated with TWS119 or DMSO control, relative proteasome activity of T cells treated with 20SPA1 or DMSO control, relative protein aggregates accumulation in T cells treated with 20SPA1 or DMSO control, and relative expression of exhaustion markers in 20SPA1-treated or DMSO control T cells.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Immunoblot analysis of β-catenin in TWS119-treated or DMSO control T cells, NFAT activity assessed by eGFP fluorescence in non-activated or activated TPR cells treated with TWS119 or DMSO control, relative proteasome activity of T cells treated with 20SPA1 or DMSO control, relative protein aggregates accumulation in T cells treated with 20SPA1 or DMSO control, and relative expression of exhaustion markers in 20SPA1-treated or DMSO control T cells.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1–S5 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Fluorochrome-conjugated antibodies and fluorescent probes used in flow cytometry, primers used for mRNA quantification by quantitative PCR, antibodies used for immunoblotting, primers used for mouse genotyping, and differentially expressed oxidized proteins in T cells treated with TWS119 or DMSO control.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1–S5 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Fluorochrome-conjugated antibodies and fluorescent probes used in flow cytometry, primers used for mRNA quantification by quantitative PCR, antibodies used for immunoblotting, primers used for mouse genotyping, and differentially expressed oxidized proteins in T cells treated with TWS119 or DMSO control.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Maximal respiration, spare respiratory capacity, and ATP-production coupled respiration of T cells across time points and oxygen conditions of the exhaustion protocol, glucose dependence and FAO and AAO capacity in T cells, compensatory glycolysis of T cells, and MitoTracker Deep Red to Green ratio in chronically stimulated T cells under normoxic or hypoxic conditions.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Maximal respiration, spare respiratory capacity, and ATP-production coupled respiration of T cells across time points and oxygen conditions of the exhaustion protocol, glucose dependence and FAO and AAO capacity in T cells, compensatory glycolysis of T cells, and MitoTracker Deep Red to Green ratio in chronically stimulated T cells under normoxic or hypoxic conditions.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Experimental workflow for sorting and treating distinct T cell phenotypes with TWS119 or DMSO.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Experimental workflow for sorting and treating distinct T cell phenotypes with TWS119 or DMSO.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Relative expression of exhaustion and activation markers on T cells across stimulations of the exhaustion protocol under normoxic or hypoxic conditions, gating strategy for T cell phenotype annotation, and gating strategy for the analysis of CD39+ and TCF7+ T cells.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Relative expression of exhaustion and activation markers on T cells across stimulations of the exhaustion protocol under normoxic or hypoxic conditions, gating strategy for T cell phenotype annotation, and gating strategy for the analysis of CD39+ and TCF7+ T cells.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Relative RNA expression of CCL3 and CRTAM across stimulations of the exhaustion protocol under hypoxic conditions, dysregulated GSEA pathways related to cell cycle progression and apoptosis between singly-stimulated and continuously stimulated T cells under hypoxia, and DEGs in chronically stimulated T cells under low glucose levels in hypoxic versus normoxic conditions.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Relative RNA expression of CCL3 and CRTAM across stimulations of the exhaustion protocol under hypoxic conditions, dysregulated GSEA pathways related to cell cycle progression and apoptosis between singly-stimulated and continuously stimulated T cells under hypoxia, and DEGs in chronically stimulated T cells under low glucose levels in hypoxic versus normoxic conditions.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Contribution of each study and cancer type to the total pool of CD8+ T cells analyzed in the single-cell dataset.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Contribution of each study and cancer type to the total pool of CD8+ T cells analyzed in the single-cell dataset.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Normalized RNA expression levels of hypoxia markers and proteasome-related genes in T cells exposed to acute hypoxia or normoxic conditions, proteasome activity in non-activated, singly-stimulated or continuously stimulated T cells under hypoxia, expression of proteasome subunit-encoding genes in murine CD8+ TILs from B16-F10 bearing mice with different expression levels of PD-1 and TIM-3 exhaustion markers, and relative RNA expression of proteasome-specific chaperones in murine TILs classified according to the expression levels of PD-1 and TIM-3 exhaustion markers.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Normalized RNA expression levels of hypoxia markers and proteasome-related genes in T cells exposed to acute hypoxia or normoxic conditions, proteasome activity in non-activated, singly-stimulated or continuously stimulated T cells under hypoxia, expression of proteasome subunit-encoding genes in murine CD8+ TILs from B16-F10 bearing mice with different expression levels of PD-1 and TIM-3 exhaustion markers, and relative RNA expression of proteasome-specific chaperones in murine TILs classified according to the expression levels of PD-1 and TIM-3 exhaustion markers.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Mean percentage of positive cells for each panel and marker.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Mean percentage of positive cells for each panel and marker.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Immunoblots of NRF1-, POMP-, and β1-overexpresing T cells, relative proteasome activity of NRF1-OE and POMP-OE T cells compared to controls, killing capacity of NRF1-OE and POMP-OE hCD19-CAR T cells against hCD19-overexpressing SK-MEL-28 melanoma cells, relative frequency of PD-1+TIM-3+LAG-3+CD39+ T cells in β1-OE or control T cells, and relative expression of TOX in β1-OE T cells or mock controls.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Immunoblots of NRF1-, POMP-, and β1-overexpresing T cells, relative proteasome activity of NRF1-OE and POMP-OE T cells compared to controls, killing capacity of NRF1-OE and POMP-OE hCD19-CAR T cells against hCD19-overexpressing SK-MEL-28 melanoma cells, relative frequency of PD-1+TIM-3+LAG-3+CD39+ T cells in β1-OE or control T cells, and relative expression of TOX in β1-OE T cells or mock controls.